Henrik Berg Rasmussen

Henrik Berg Rasmussen is a Lecturer at the Department of Biomedical Sciences, University of Copenhagen, specializing in Nutritional Immunology. His research spans pharmacology, genetics, and immunology with a particular focus on drug development for viral infections and genetic factors in mental disorders.

His research interests primarily center around Nutritional Immunology, Pharmacology of antiviral agents, and Genetic factors in schizophrenia and mental disorders. Dr. Rasmussen has made significant contributions to understanding the pharmacokinetics of nucleoside analogs like GS-441524 and Molnupiravir for COVID-19 treatment, as well as investigating genetic variants related to carboxylesterase 1 and their implications for drug metabolism.

His publication trends show a strong focus on interdisciplinary research connecting pharmacology with genetics, particularly in the areas of antiviral therapeutics and psychiatric genetics. Recent work has centered on critical assessment of COVID-19 treatments, while earlier work focused on schizophrenia genetics and enzyme function.

Dr. Rasmussen collaborates extensively with researchers across multiple institutions, as evidenced by his co-authorship on large consortium papers including the Schizophrenia Working Group of the Psychiatric Genomics Consortium and the Wellcome Trust Case Control Consortium 2.

His laboratory work appears to focus on the intersection of nutritional science and immunology, with particular attention to how genetic variations affect drug metabolism and response, though specific lab details aren't provided in the available information.